

Marfan Syndrome

Indications for Ordering

- Confirm diagnosis for individuals with suspected Marfan syndrome (MFS)
- Determine the specific *FBN1* gene variant in known affected individual
- Determine disease status in children or other at-risk family members of affected individuals

Test Description

- Sequencing
 - Polymerase chain reaction followed by bidirectional sequencing of *FBN1* coding regions and intron/exon boundaries
- Deletion/duplication analysis
 - Multiplex ligation-dependent probe amplification

Tests to Consider

Primary tests

[Marfan Syndrome \(*FBN1*\) Sequencing and Deletion/Duplication 2005584](#)

- Preferred test to confirm diagnosis when MFS is strongly suspected by consensus criteria

[Marfan Syndrome, *FBN1* Sequencing 2005589](#)

- Acceptable test to confirm diagnosis for individuals with clinical phenotype of MFS

Related tests

[Aortopathy Panel, Sequencing and Deletion/Duplication 2006540](#)

- Preferred panel for individuals with clinical phenotype of aortic or vascular aneurysm, dissection, or rupture if no single specific diagnosis is strongly suspected

[Familial Mutation, Targeted Sequencing 2001961](#)

- Useful when a pathogenic familial variant identifiable by sequencing is known

Disease Overview

Prevalence – 1/5,000-10,000

Symptoms

- MFS is a connective tissue disorder
- A clinical diagnosis of MFS in an individual **without a family history** of MFS (Shprintzen-Goldberg syndrome [SGS], Loeys-Dietz syndrome [LDS], and Ehlers-Danlos syndrome type IV [EDS IV] have been excluded) is based on the presence of any of the following
 - Aortic root dilatation or dissection and ectopia lentis
 - Aortic root dilatation or dissection and pathogenic *FBN1* variant
 - Ectopia lentis and an *FBN1* gene variant previously reported to be associated with cardiovascular disease
 - Aortic root dilatation or dissection and at least seven points from the table below

Revised Ghent Nosology (Loeys, 2010) Point Values for Specific Characteristics	
Characteristics	Point Value
Wrist AND thumb sign	3
Wrist OR thumb sign	1
Pectus carinatum	2
Pectus excavatum or chest asymmetry	1
Hindfoot deformity	2
Plain des planus	1
Pneumothorax	2
Dural ectasia	2
Acetabular protrusion	2
Reduced upper segment-to-lower segment (US/LS) ratio AND increased arm span-to-height ratio AND no severe scoliosis	1
Scoliosis or thoracolumbar kyphosis	1
Reduced elbow extension	1
Skin striae	1
Myopia >3 diopters	1
Mitral valve prolapse (all types)	1
Characteristic facial features	1
Score ≥7 indicates systemic involvement	

- A clinical diagnosis of MFS in an individual **with a family history** of MFS (SGS, LDS, and EDS IV have been excluded) is based on the presence of any of the following
 - Ectopia lentis
 - Systemic findings scoring seven points or higher (refer to table of point values, above)
 - Aortic root dilation or dissection

- Other disorders associated with *FBN1* gene variants
 - Neonatal MFS – atrioventricular valve dysfunction, pulmonary emphysema, joint contractures, crumpled ears, and loose skin
 - MFS phenotype with severe congenital lipodystrophy and progeroid-like appearance
 - Mitral valve prolapse syndrome – mitral valve prolapse, pectus excavatum, scoliosis, mild arachnodactyly
 - Familial ectopia lentis – bilateral ectopia lentis, sometimes scoliosis
 - MASS syndrome – mitral valve prolapse, aortic enlargement, skin, skeletal findings
 - Weill-Marchesani syndrome type 2 – ectopia lentis, brachydactyly, joint stiffness, short stature
 - SGS – craniosynostosis, arachnodactyly, brachycephaly, pectus deformities, scoliosis, mental retardation, rarely aortic root dilatation
 - Aortic aneurysm, ascending and dissection
 - Acromicric dysplasia
 - Geleophysic dysplasia type 2
 - Stiff skin syndrome

Treatment issues

Early diagnosis is crucial for treatment of skeletal, orthopedic, and cardiovascular abnormalities

Genetics

Gene – *FBN1*

Inheritance – autosomal dominant

Penetrance – high variability; age dependent

De novo variants– 25% of cases

- Nonsense
- In- or out-of-frame deletions/insertions
- Splice-site variants
- Missense variants
 - Involve cysteine residues
 - Affect epidermal growth factor-like consensus sequences absent in 400 ethnically matched controls

Pathogenic variants

- The revised Ghent nosology defines causal *FBN1* variants
- Variants segregate with disease in MFS families
- Few genotype/phenotype correlations
- MFS with *FBN1* variants identified in exons 24-32 generally have a severe prognosis
- Exon 64 frameshift variants reported in individuals with Marfan phenotype, generalized lipodystrophy, and progeroid facial appearance
- Large genomic deletions of regulatory elements have been reported in individuals with MFS or MFS spectrum disorders, including MASS phenotype

Test Interpretation

Sensitivity/specificity

- Clinical sensitivity
 - Sequencing – ranges from 70-93%; dependent on accuracy of clinical diagnosis (Dietz, 2017; Korkko, 2002)
 - Deletion/duplication analysis – unknown
- Analytical sensitivity/specificity – 99%

Results

- Positive – known pathogenic *FBN1* variant detected
 - Individual predicted to be affected with MFS or *FBN1*-related disorder in a symptomatic individual
- Negative – no known pathogenic *FBN1* variant detected
 - Reduces risk, but does not exclude the diagnosis of MFS
- Inconclusive – variant of uncertain clinical significance may be detected

Limitations

- Not determined or evaluated
 - Deep intronic pathogenic variants
 - Regulatory region pathogenic variants
 - Large deletions/duplications of exon 40 may or may not be detected, depending on the location of breakpoints
 - Breakpoints of large *FBN1* deletions/duplications
- Variants in genes other than *FBN1* Diagnostic errors can occur due to rare sequence variations
- Do not use for prenatal testing for an unknown *FBN1* variant

References

- Dietz HC. Marfan Syndrome. 2001 Apr 18 [Updated 2017 Feb 2]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. (www.ncbi.nlm.nih.gov/books/NBK1335/)
- Korkko J, et al. Sensitivity of conformation sensitive gel electrophoresis in detecting mutations in Marfan syndrome and related conditions. *J Med Genet.* 2002;39:34-41.
- Kumar A, Agarwal S. Marfan syndrome: An eyesight of syndrome. *Meta Gene.* 2014;2:96-105.
- Loeys BL, Dietz HC, et al. The revised Ghent nosology for the Marfan syndrome. *J Med Genet.* 2010;47:476-485